La vendita allo scoperto per IQVIA Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di IQVIA Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

IQVIA Hldgs (NYSE:IQV) Azioni, Report sulle vendite allo scoperto

IQVIA Hldgs

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings

IQVIA Holdings Inc

IQVIA HOLDINGS ORD

WIIM

Sherwin-Williams shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

NVDA

NVIDIA shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

News

Offerings

RDZN

Roadzen Files For Mixed Shelf Of Up To $100M

Contracts

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

The Symplicity &#x2122; blood pressure procedure offers patients a new adjunct approach to lowering blood pressure&nbsp;
GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122;&nbsp;renal denervation (RDN) catheter, used in the Symplicity&#x2122;&nbsp;blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

Biotech

General

CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025

Titan International Files For Offering Of Up To 11.92M Shares By The Selling Stockholders

NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) today announced it has commenced a proposed underwritten public offering in the United States (the "Registered Offering"). Concurrently, the Company has also commenced a private placement (the "Private Offering" and, together with the Registered Offering, the "Offerings").
The Registered Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Registered Offering may be completed, or as to the actual size, pricing or other terms of the Registered Offering. In addition, the Company intends to grant the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of initial common shares and/or an additional 15 percent of the number of initial warrants offered in the Registered Offering.
The Private Offering consists of common shares and warrants to purchase common shares. There can be no assurance as to whether or when the Private Offering may be completed, or as to the actual size, pricing or other terms of the Private Offering. Completion of the Private Offering is not contingent on completion of the Registered Offering and completion of the Registered Offering is not contingent on the completion of the Private Offering.
Maxim Group LLC is acting as sole book-running manager and underwriter for the Registered Offering.
NioCorp currently intends to use the net proceeds from the Offerings for working capital and general corporate purposes, including to (i) advance its efforts to launch construction of a critical minerals project in Southeast Nebraska (the "Elk Creek Project") and move it to commercial operation and (ii) repay all amounts outstanding under the Company's $2.0 million non-revolving multiple draw credit facility (the "Smith Credit Facility") available pursuant to the Loan Agreement, dated September 11, 2024, by and between the Company and its Chief Executive Officer, President and Executive Chairman, Mark Smith. The Smith Credit Facility will continue to be available to the Company following the close of the Offerings.
The Registered Offering is subject to customary closing conditions.

NioCorp Announces Commencement Of Proposed Underwritten Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed

CHWY

Chewy shares are trading higher after it was announced that the company will join the S&P MidCap 400 prior to the opening of trading on Wednesday, November 6, 2024.

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf</a>

Markets

NVIDIA And Sherwin-Williams Set To Join Dow Jones Industrial Average; Vistra To Join Dow Jones Utility Average

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf</a>

SRCL

Chewy Set to Join S&P MidCap 400; Chewy Will Replace Stericycle Inc In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Wednesday, November 6

<a href="https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans">https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans</a>
Tesla Inc. sold $499 million of bonds backed by loans offered to customers buying solar equipment.

Financing

Asset Sales

TSLA

'Tesla Sells $499M Of Debt Backed by Solar Equipment Loans' - Bloomberg News

EVTV

Envirotech Vehicles Files Prospectus Relates To Resale, From Time To Time, Of Up To 13.6M Shares Of Common Stock

Global

BORR

Borr Drilling Limited Announces Voluntary Delisting From Oslo Stock Exchange; Co's Shares Will Be Delisted From OSE As Of 31 December 2024

ONCO

Onconetix Files For Resale Of Up To 10,586,556 Shares By The Selling Stockholders; Offering Up To 6.25M Shares Of Common Stock

- SEC Filing&nbsp;
On October 30, 2024, the Company received a letter from Nasdaq notifying the Company that, the Company had not regained compliance with the MVLS Requirement within the Cure Period. As a result, Nasdaq has determined to delist the Company's securities from Nasdaq on November 8, 2024, subject to the Company's right to appeal described below.
&nbsp;
On October 31, 2024, the Company requested a hearing to appeal such determination before a panel (the "Hearings Panel"). The hearing request will stay the suspension of the trading of the Company's common stock pending such hearing or any extension provided by the Hearings Panel.
&nbsp;
At such hearing, the Company intends to submit a plan to regain compliance with the MVLS Requirement and with other deficiencies in its compliance with Nasdaq listing requirements that have been previously disclosed, including the failure to comply with the minimum bid price requirement disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2024.
&nbsp;
No assurances can be provided that the Company will obtain a favorable decision from the Hearings Panel, and/or that the Company will be able to regain or maintain compliance with Nasdaq listing's rules.

CERO

CERo Therapeutics Received A Letter From Nasdaq Notifying The Company That It Had Not Regained Compliance With The MVLS Requirement Within The Cure Period; Nasdaq Has Determined To Delist The Company's Securities From Nasdaq On November 8, 2024; On October 31, 2024, The Co Requested A Hearing To Appeal The Determination Before A Panel

BNTC

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

Super League Enterprise 13G Filing Shows Infinite Reality, Inc. Reported A 9.2% Stake In The Co As Of October 29, 2024

ITT Files For Mixed Shelf; Size Not Disclosed

ADAP

Adaptimmune Therapeutics Receives Nasdaq Notice For Non-Compliance With Minimum Bid Price

Marti Technologies, Inc. ("Marti" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRT#NYSE">MRT</a>), Türkiye's leading mobility super app, today announced that it has appointed Deniz Terlemez as its new Interim Chief Financial Officer ("CFO"), effective November 1, 2024. Deniz Terlemez succeeds Oguz Erkan, the Company's former CFO. Mr. Terlemez served as the Company's Finance Director before his appointment as Interim CFO.

Management

Marti Technologies Appoints  Deniz Terlemez As New Interim Chief Financial Officer, Effective November 1, 2024

Here's the major earnings before the open tomorrow

IQVIA Non-GAAP EPS of $2.84 beats by $0.03, revenue of $3.89B beats by $30M

Reports Q3 revenue $3.9B, consensus $3.86B…"IQVIA (IQV) reported strong third quarter results," stated Ari Bousbib, chairman and CEO of IQVIA. "We ...

Iqvia reports Q3 EPS $2.84, consensus $2.81

IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV – Research Report), Alphatec Hol...

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Alphatec Holdings (ATEC) and Alnylam Pharma (ALNY)

Analyst Michael Ryskin from Bank of America Securities reiterated a Buy rating on IQVIA Holdings (IQV – Research Report) and decreased the price ta...

Resilient Performance and Strategic Growth Drive IQVIA Holdings Buy Rating

Barclays lowered the firm's price target on Iqvia (IQV) to $255 from $260 and keeps an Overweight rating on the shares post the Q3 report. The comp...

Iqvia price target lowered to $255 from $260 at Barclays

Baird lowered the firm's price target on Iqvia (IQV) to $223 from $256 and keeps a Neutral rating on the shares. The firm said they are concerned a...

Iqvia price target lowered to $223 from $256 at Baird

TD Cowen lowered the firm's price target on Iqvia (IQV) to $255 from $270 and keeps a Buy rating on the shares. The firm said the company has faced a

Iqvia price target lowered to $255 from $270 at TD Cowen

Deutsche Bank analyst Justin Bowers lowered the firm's price target on Iqvia (IQV) to $265 from $270 and keeps a Buy rating on the shares. Publishe...

Iqvia price target lowered to $265 from $270 at Deutsche Bank

ABEV

AGIO

ALGM

ALNY

AMKBY

APTV

ARGX

ATEC

ATGFF

AVNT

BALL

BAND

BBVA

BNPQF

CCRD

CIFR

CMCSA

CMPS

CPSH

DFIN

DINO

FLWS

FNMA

GNRC

GPRE

IDCC

IDXX

INSM

ISNPY

ITRI

Press Releases

IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024

IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group

IQVIA Reports Second-Quarter 2024 Results

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024

Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative

IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award

IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™

IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024

IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day

AVAI

EXAI

RXRX

TWST

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

IQVIA Hldgs

Vendite allo scoperto

IQVIA Hldgs (NYSE:IQV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO